brivaracetam · Ucb Inc · NDA 205836, 205837, 205838
Briviact
Earliest generic entry, as listed · earliest of 7 marketed strengths
9 Apr 2030
2 of 7 marketed strengths have no unexpired patent or exclusivity listed.
Blocked by patent: US 10729653.
Listed patents · 1 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 10729653 | product | 9 Apr 2030 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
- 25 Oct 2026Generic approved · 205838-00123 Feb 2026
- 25 Oct 2026Generic approved · 205836-0018 Sep 2026
- 25 Oct 2026Generic approved · 205838-00123 Feb 2026
- 25 Oct 2026Generic approved · 205838-00120 Oct 2026
- 25 Oct 2026Generic approved · 205836-0011 Jul 2026
- 25 Oct 2026First generic approved · 205837-00123 Feb 2026
- 25 Oct 2026Generic approved · 205837-00123 Feb 2026
- 25 Oct 2026Generic approved · 205836-00113 Nov 2025
- 25 Oct 2026First generic approved · 205838-00119 Feb 2026
- 25 Oct 2026Generic approved · 205838-00119 Feb 2026
- 25 Oct 2026Generic approved · 205836-00123 Feb 2026
- 25 Oct 2026Generic approved · 205837-00113 Jul 2026
- 25 Oct 2026Generic approved · 205838-00123 Feb 2026
- 25 Oct 2026First generic approved · 205837-00123 Feb 2026
- 25 Oct 2026Generic approved · 205837-00123 Feb 2026
- 25 Oct 2026Generic approved · 205836-00123 Feb 2026
- 25 Oct 2026First generic approved · 205837-00123 Feb 2026
- 25 Oct 2026Generic approved · 205837-00123 Feb 2026
- 25 Oct 2026Generic approved · 205838-00123 Feb 2026
- 25 Oct 2026Generic approved · 205838-00110 Aug 2026
Products covered · 7
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 205836 · 001 · RLD | tablet, oral | 10MG | 9 Apr 2030 |
| 205836 · 002 · RLD | tablet, oral | 25MG | 9 Apr 2030 |
| 205836 · 003 · RLD | tablet, oral | 50MG | 9 Apr 2030 |
| 205836 · 004 · RLD | tablet, oral | 75MG | 9 Apr 2030 |
| 205836 · 005 · RLD | tablet, oral | 100MG | 9 Apr 2030 |
| 205837 · 001 · RLD | solution, intravenous | 50MG/5ML (10MG/ML) | open |
| 205838 · 001 · RLD | solution, oral | 10MG/ML | open |
Expired or delisted (3)
- US 6911461 · substance, product, use U-2295 · 21 Feb 2026
- US 6911461 · substance, product, use U-1815 · 21 Feb 2026
- US 6911461 · substance, product, use U-2130 · 21 Feb 2026